New York State Common Retirement Fund Has $1.26 Million Position in Codexis, Inc. (NASDAQ:CDXS)

New York State Common Retirement Fund increased its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 22.6% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 61,280 shares of the biotechnology company’s stock after acquiring an additional 11,280 shares during the period. New York State Common Retirement Fund’s holdings in Codexis were worth $1,258,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of CDXS. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Codexis by 152.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 1,711 shares during the last quarter. Legal & General Group Plc raised its position in Codexis by 12.1% in the 4th quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 1,010 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Codexis by 13.3% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 1,186 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Codexis in the 4th quarter valued at $217,000. Finally, BNP Paribas Arbitrage SA raised its position in Codexis by 67,343.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,791 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 10,775 shares during the last quarter. Hedge funds and other institutional investors own 85.51% of the company’s stock.

NASDAQ CDXS opened at $17.45 on Friday. Codexis, Inc. has a 52 week low of $12.85 and a 52 week high of $23.05. The company has a current ratio of 3.42, a quick ratio of 3.38 and a debt-to-equity ratio of 0.51.

Codexis (NASDAQ:CDXS) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). The company had revenue of $15.58 million during the quarter, compared to analysts’ expectations of $14.83 million. Codexis had a negative return on equity of 21.08% and a negative net margin of 18.22%. As a group, equities analysts anticipate that Codexis, Inc. will post -0.23 EPS for the current fiscal year.

In other news, insider John J. Nicols sold 55,072 shares of Codexis stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $20.83, for a total value of $1,147,149.76. Following the completion of the sale, the insider now directly owns 1,087,751 shares of the company’s stock, valued at approximately $22,657,853.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James Lalonde sold 19,999 shares of Codexis stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $18.65, for a total value of $372,981.35. The disclosure for this sale can be found here. Insiders sold a total of 155,071 shares of company stock valued at $3,190,531 over the last three months. Insiders own 10.70% of the company’s stock.

Several brokerages have issued reports on CDXS. BidaskClub downgraded Codexis from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a research report on Friday, May 10th. ValuEngine upgraded Codexis from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. HC Wainwright lifted their target price on Codexis to $22.50 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, Craig Hallum lifted their target price on Codexis from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Codexis has an average rating of “Buy” and an average target price of $21.07.

TRADEMARK VIOLATION WARNING: “New York State Common Retirement Fund Has $1.26 Million Position in Codexis, Inc. (NASDAQ:CDXS)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/06/16/new-york-state-common-retirement-fund-has-1-26-million-position-in-codexis-inc-nasdaqcdxs.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Article: Net Margin – Understanding the Different Kinds of Profit

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.